Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate

(2010) S. B. Cohen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

(2009) D E Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

(2009) A Finckh et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

(2009) Josef S Smolen et al.   LANCET

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

(2008) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

(2008) T R D J Radstake et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy

(2008) E. Keystone et al.   ARTHRITIS AND RHEUMATISM

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

(2008) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Rheumatoid Arthritis

(2008) Joseph R Lutt et al.   DRUGS

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug

(2008) K. L. Hyrich et al.   RHEUMATOLOGY